Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Cash & Equivalents came in at $175.7 million in Q2 2026, down 42.92% YoY from $307.8 million in Q2 2025, and down 7.52% on a QoQ basis from $190.0 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Cash & Equivalents data on file, last reported at $175.7 million in Q2 2026.
- Quarterly Cash & Equivalents fell 42.92% year-over-year to $175.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $175.7 million (down 42.92% YoY) and the FY2025 annual result came in at $165.6 million, down 9.8% from the prior year.
- Cash & Equivalents eased to $175.7 million in Q2 2026, from $190.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $352.1 million in Q3 2025 to a low of $108.0 million in Q4 2023.
- A 5-year average of $199.3 million and a median of $188.7 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 44.86% — and 2024, when it jumped 70.05%.
- Tracing KNSA's Cash & Equivalents over 5 years: stood at $122.7 million in 2022, then decreased by 12.03% to $108.0 million in 2023, then surged by 70.05% to $183.6 million in 2024, then fell by 9.8% to $165.6 million in 2025, then rose by 6.09% to $175.7 million in 2026.
- The last three Cash & Equivalents figures came in at $175.7 million (Q2 2026), $190.0 million (Q1 2026), and $165.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.04 Bn | 5.52 Bn | 220.03 Mn | 175.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175.68 Mn |
| Mar 31, 2026 | 189.95 Mn |
| Dec 31, 2025 | 165.60 Mn |
| Sep 30, 2025 | 352.10 Mn |
| Jun 30, 2025 | 307.78 Mn |
| Mar 31, 2025 | 268.34 Mn |
| Dec 31, 2024 | 183.58 Mn |
| Sep 30, 2024 | 223.78 Mn |
| Jun 30, 2024 | 218.76 Mn |
| Mar 31, 2024 | 213.55 Mn |
| Dec 31, 2023 | 107.95 Mn |
| Sep 30, 2023 | 201.08 Mn |
| Jun 30, 2023 | 184.99 Mn |
| Mar 31, 2023 | 187.49 Mn |
| Dec 31, 2022 | 122.72 Mn |
| Sep 30, 2022 | 200.72 Mn |
| Jun 30, 2022 | 138.21 Mn |
| Mar 31, 2022 | 145.58 Mn |
| Dec 31, 2021 | 122.47 Mn |
| Sep 30, 2021 | 200.18 Mn |